Ambea CEO Mark Jensen has indicated that the Swedish animal health company will continue its acquisition strategy, even as the firm’s debt load rises following its recent bid for competitor Humana.
Jensen stated that the company retains the financial strength to pursue additional transactions, signaling that the current leverage levels are not seen as a barrier to further growth.
The comments come as Ambea navigates a period of aggressive expansion in the animal health sector.
The recent bid for Humana marks a significant step in consolidating market share, but Jensen’s remarks suggest this is part of a broader, ongoing strategy rather than a one-off move.
Investors will be watching to see how the company balances this growth ambition with the increased financial risk associated with higher debt levels.
The animal health industry has seen a wave of consolidation activity, with peers like Vimian also accelerating their growth through acquisitions and new product launches.